Humpton, Timothy J. http://orcid.org/0000-0002-8030-9539
Hall, Holly http://orcid.org/0000-0003-2779-2565
Kiourtis, Christos
Nixon, Colin http://orcid.org/0000-0002-8085-2160
Clark, William
Hedley, Ann
Shaw, Robin
Bird, Thomas G.
Blyth, Karen
Vousden, Karen H. http://orcid.org/0000-0002-7365-1766
Funding for this research was provided by:
Cancer Research UK (C596/A26855, FC001557, C596/A17196, C596/A17196, C596/A17196, A26813, C596/A17196, C596/A26855, FC001557)
RCUK | MRC | Medical Research Foundation (FC001557, FC001557)
Wellcome Trust (FC001557, WT107492Z, WT107492Z, WT107492Z, FC001557)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N017005/2)
Article History
Received: 27 November 2020
Revised: 26 August 2021
Accepted: 7 September 2021
First Online: 9 October 2021
Competing interests
: KHV is on the board of directors and a shareholder of Bristol Myers Squibb, and on the science advisory board (with stock options) of PMV Pharma, RAZE Therapeutics and Volastra Therapeutics, Inc. She is also on the SAB of Ludwig Cancer Research. KHV is a co-founder and consultant of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of Patent Application WO/2017/144877. TGB is in receipt of research funding from AstraZeneca.
: Procedures involving mice were performed under Home Office licence numbers 70/8645, PP6345023, and 70/8891. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010 and sanctioned by Local Ethical Review Process (University of Glasgow). No human samples were used in this study.